TransMedics Group, Inc. (NASDAQ:TMDX)
| Market Cap | 2.74B-32.9% |
| Revenue (ttm) | 668.47M+25.8% |
| Net Income | 151.70M+111.7% |
| EPS | 3.86+100.0% |
| Shares Out | 34.56M |
| PE Ratio | 17.92 |
| Forward PE | 35.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,048.966 |
| Open | 80.25 |
| Previous Close | 81.07 |
| Day's Range | 77.70 - 80.28 |
| 52-Week Range | 60.10 - 156.00 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 99.75(+25.96%) |
| Earnings Date | Nov 4, 2026 |
TransMedics Group, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About TMDX
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TMDX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TMDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TMDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TMDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TMDX Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Cost of net product revenue | $111.16M | 50.17% |
| Cost of service revenue | $78.79M | 35.56% |
| Research, development and clinical trials | $31.63M | 14.28% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TMDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TMDX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TMDX
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $168.03M |
| VTIVanguard Morningstar Total Stock Market ETF | $88.39M |
| IWMiShares Russell 2000 ETF | $72.77M |
| VBVanguard Morningstar Small-Cap ETF | $64.06M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $36.70M |
| VXFVanguard Extended Market ETF | $34.10M |
Estimated from each fund’s disclosed top holdings × AUM
TMDX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TMDX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score